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These abstracts were presented as part of the ‘Iressa’ Clinical Experience
(ICE) meeting held in Madrid in June 2003 and are reproduced with the
authors’ permission. Data from several of these abstracts have subsequently
been published (full references are shown in the journal articles in which
the ICE abstracts are cited) and further publications are expected.
Antitumour effect of eighth-line gefitinib
(‘Iressa’, ZD1839) in a heavily pretreated patient with
adenocarcinoma of unknown primary origin
(probably pulmonary)
A Awada
1 and J Klastersky
1
1Institut Jules Bordet, Brussels, Belgium
This case report describes the objective response of a 70-year-old, heavily
pretreated male smoker with adenocarcinoma of unknown primary origin
(probably pulmonary) following eighth-line gefitinib (‘Iressa’, ZD1839)
therapy. In February 1996 he presented with adenocarcinoma, and over the
next 5 years received seven lines of chemotherapy (gemcitabine; ifosfamide
plus a platinum-based agent; paclitaxel; 5-fluorouracil; docetaxel plus
farnesyltransferase inhibitor; vinorelbine; and doxorubicin plus temozolo-
mide) along with radiotherapy for brain metastases. Objective responses
were seen when docetaxel plus a farnesyltransferase inhibitor and
vinorelbine were used, and stable disease was observed following treatment
with paclitaxel. In April 2001, echography and CT scans found metastases
in the cervical lymph nodes (LN), liver and mediastinum, and lactate
dehydrogenase (LDH) and carcinoembryonic antigen (CEA) levels were
258UL
 1 (normally 120–140UL
 1) and 22.3mgL
 1 (normally 0–
2.5mgL
 1), respectively. At this time, the patient began taking
250mgday
 1 gefitinib orally, as part of the ‘Iressa’ Expanded Access
Programme, concomitantly with atenolol. At 67 days after beginning
gefitinib therapy, complete responses were observed in the cervical LN and
liver metastases, and a partial response was seen in the mediastinum
metastases; LDH levels were 143UL
 1 and CEA levels were 2.3mgL
 1
(confirmed 15 days later). Gefitinib was well tolerated and the only adverse
event noted was pruritus. The last contact with the patient was 113 days
after starting gefitinib therapy, by which time his quality of life and lifestyle
had both improved. However, the patient died suddenly after this, with the
cause of death thought to be cardiac in origin.
Gefitinib (‘Iressa’, ZD1839) as third-line therapy for a
patient with symptomatic brain metastases from non-
small-cell lung cancer
M Aze ´mar
1, C Stoll
1 and C Unger
1
1Tumour Biology Clinic, Freiburg, Germany
A 57-year-old male smoker was diagnosed with stage IIIb non-small-cell
lung cancer (NSCLC) in April 2000 with extended pleural carcinosis of the
left lung and exterior pericardial carcinomatosis. Bleomycin plus tetra-
cycline was given initially followed by gemcitabine; a second pleurodesis
with tetracycline did not prevent further pleural effusion. Treatment with
cisplatin plus gemcitabine (four cycles) and therapy with an Ep-Cam
directed antibody, IGN 101, led to disease stabilisation for 18 months.
In February 2002, two small brain lesions were detected and treated
with radiation (20Gy each) followed by adjuvant cisplatin plus gemcitabine
(three cycles). Oral gefitinib (‘Iressa’, ZD1839) 250mgday
 1 was started in
June 2002 to consolidate the disease stabilisation. After 1 month, the patient
reported neurological symptoms (left hemiparesis and imbalance) and
underwent surgery to remove the main lesion. Antiepileptic medication was
prescribed after convulsions in August 2002. The patient was hospitalised
in November 2002 for neurological symptoms and again in January
2003 for phlebothrombosis and Gram-negative sepsis. Radiological
assessment confirmed stabilisation of the primary tumour. The patient
reported no adverse reactions to gefitinib, other than the neurological
symptoms. In February 2003, gemcitabine and cisplatin were resumed to
treat the brain metastases and rising carcinoembryonic antigen levels.
However, the patient died 2 weeks later after a generalised seizure. In
conclusion, the primary tumour was stabilised by third-line gefitinib
therapy for 8 months. The patient’s general condition was limited only by
neurological symptoms caused by previously irradiated brain metastases.
This tumour control in conjunction with surgery for cranial metastases
might be of further interest, as the primary tumour did not directly
contribute to this patient’s death.
Use of gefitinib (‘Iressa’, ZD1839) in advanced
non-small-cell lung cancer for routine clinical practice
J Bendel
1,JH a ¨usler
1, S Korfee
1, G Antoch
1, T Gauler
1 and
W Eberhardt
1
1University Hospital Essen, Essen, Germany
From March 2002 to February 2003, 50 patients (34 male, 16 female)
received oral gefitinib (‘Iressa’, ZD1839) 250mgday
 1 treatment as part of
the ‘Iressa’ Expanded Access Programme. At the start of gefitinib
treatment, the median age was 60.5 (range 34–78) years and the median
Eastern Cooperative Oncology Group performance status was 1 (range 0–
2). Most patients in this series had stage IV metastatic disease and
approximately 50% had adenocarcinoma. The median number of prior
chemotherapy regimens was two (range 0–6), with approximately 90% of
pretreated patients having received a platinum-based regimen. Six patients
were chemonaive and 31 patients had received previous radiotherapy. The
median duration of gefitinib treatment was 12.5 (range 1–46) weeks. In 21
patients a temporary halt of tumour growth, documented by radiological
imaging X4 weeks from the start of treatment, has been observed; of these,
four patients experienced a partial response, three of whom had
demonstrated a response to previous treatment. At the time of writing,
for patients demonstrating a response to gefitinib, the median duration of
disease control was 18 (range 4–46) weeks and tumour control maintained
for X25 weeks was observed in seven patients. Ten patients continue on
gefitinib treatment and 36 (72%) patients remain alive. We have observed a
trend in symptom improvement and preliminary results from quality-of-
life analysis suggest that an improvement of dyspnoea is the most
important surrogate marker of an improvement in patients’ well-being. In
conclusion, in this series of patients with advanced non-small-cell lung
cancer, gefitinib has caused symptom improvement and a prolonged period
of tumour control.
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stage IIIb-IV non-small-cell lung cancer entering the
‘Iressa’ Expanded Access Programme at the University
Federico II, Naples
AR Bianco
1, V Damianov
1, E Matano
1 and R Bianco
1
1University Federico II School of Medicine, Naples, Italy
A total of 82 patients with advanced non-small-cell lung cancer (NSCLC) who
had failed previous chemotherapy (at least two lines of chemotherapy
including cisplatin and taxanes) entered the ‘Iressa’ Expanded Access
Programme at our institution from September 2001 to April 2003. Eight
patients had brain metastases (treated with radiotherapy), seven patients had
received radiotherapy for bone metastases, seven patients had received
radiotherapy for lung metastases and 13 patients had obtained a partial
remission following chemotherapy. All patients were given 250mgday
 1
gefitinib (‘Iressa’, ZD1839) orally. In all, 65 patients met the eligibility criteria,
and 49 have completed X3 months of therapy and are, therefore, evaluable.
Patient demography is as follows: male:female, 35:14 patients; median age 59
(range 29–80) years; Eastern Cooperative Oncology Group performance
status p2; squamous-cell carcinoma, 23 patients; adenocarcinoma (including
one patient with bronchioloalveolar), 25 patients; large-cell carcinoma, one
patient; and stage IIIb/IV disease, eight out of 41 patients. One female patient
with adenocarcinoma (plus brain and lung metastases) has experienced a
complete response. After 3 months of therapy, 18 patients had stable disease
(SD) and 30 patients had progressive disease (PD). At 6 months, three
patients had SD and nine patients had PD, and at 9 months, three patients had
SD. After 1 year, two patients (one still receiving gefitinib) had SD. The
tolerability of gefitinib was good, with two patients experiencing mild, drug-
related skin rash. Although the response rate was low, gefitinib offers definite
palliation in pretreated advanced NSCLC, with few side effects.
Refractory non-small-cell lung cancer: clinical
experience with gefitinib (‘Iressa’, ZD1839) in 28
patients who entered the ‘Iressa’ Expanded Access
Programme at the Sydney Cancer Centre
M Boyer
1
1Sydney Cancer Centre, Sydney, Australia
A total of 40 patients with non-small-cell lung cancer (NSCLC) who had
received prior chemotherapy or were unsuitable for chemotherapy entered
the ‘Iressa’ Expanded Access Programme at the Sydney Cancer Centre from
September 2001 to April 2003. Patients who had previously received gefitinib
(‘Iressa’, ZD1839) were excluded. Data are presented here for the first 28
patients (19 men, nine women) studied. The most common histology was
adenocarcinoma (12 patients), followed by large cell (seven patients),
squamous cell (six patients) and bronchioloalveolar (three patients). The
majority of patients (17 out of 28, 61%) had an Eastern Cooperative Oncology
Group performance status (PS) of 1; two had a PS of 0, five had a PS of two
and 2 had a PS of 3 (PS was unknown for 2 patients). Five patients had not
received prior chemotherapy. Other patients had received one, two or three
chemotherapy regimens (12, seven and four patients, respectively). All
patients received gefitinib 250mgday
 1. Disease progression was assessed
every 8–12 weeks. Four patients had a partial response, three patients had
stable disease and 17 patients had progressive disease (four patients were not
assessable). The median duration of treatment was 70 days for non-
responders and 222 days for responders. The median survival was 154 days.
In total, 16 (57%) patients experienced rash, four (14%) reported diarrhoea
and two (7%) reported nausea and vomiting. These results indicate that
gefitinib may have a role in the treatment of some patients with NSCLC.
Gefitinib (‘Iressa’, ZD1839) in patients with brain
metastases from non-small-cell lung cancer: report of
four cases
F Cappuzzo
1, A Ardizzoni
2, H Soto-Parra
3, C Gridelli
4,
P Maione
4, M Tisea
2, C Calandri
1, S Bartolini
1, A Santoro
3
and L Crino `1 [a]
1Bellaria Hospital, Bologna, Italy;
2Istituto Nazionale per la Ricerca
sul Cancro, Genoa, Italy;
3Istituto Clinico Humanita-Rozzano,
Milano, Italy;
4S.G Moscati Hospital, Avellino, Italy
Four patients (aged 47–65 years; male:female, 1:3) with non-small-cell
lung cancer (NSCLC) and brain metastases received gefitinib (‘Iressa’,
ZD1839) 250mgday
 1 as part of the ‘Iressa’ Expanded Access Programme.
All patients had adenocarcinoma. Two patients were non-smokers and two
had a prior smoking history. All patients had previously been treated with
at least two lines of chemotherapy including at least one platinum-based
regimen. In addition, three patients had received prior whole-brain
radiotherapy, terminated at least 3 months before starting gefitinib. After
3 months, one patient had a complete response in the brain with
stabilisation of extracranial disease, while the other three patients partially
responded to gefitinib, both in the brain and extracranial sites. Treatment
duration was 3þ, 5, 7 and 12þ months. Gefitinib was generally well
tolerated, with skin toxicity recorded in two patients (grade 1/2). All
patients experienced symptomatic improvement while on gefitinib therapy.
The presence of brain metastases has been an exclusion criterion in clinical
studies to date. However, this case study suggests that gefitinib is effective
in patients with previously treated brain metastases and warrants further
investigation.
Gefitinib (‘Iressa’, ZD1839) in patients with brain
metastases from non-small-cell lung cancer: report of
four cases
F Cappuzzo
1, C Calandri
1, S Bartolini
1 and L Crino `1 [b]
1Bellaria Hospital, Bologna, Italy
Four patients (two male, two female) aged 53–65 years with non-small-cell
lung cancer (NSCLC): adenocarcinoma (two patients), squamous-cell
carcinoma (one patient) and bronchioloalveolar carcinoma (one patient),
developed brain metastases (BM) and extracranial disease. All the patients
had previously received first-line platinum-based chemotherapy, and two
patients had received whole-brain radiotherapy for BM. Gefitinib (‘Iressa’,
ZD1839) 250mgday
 1 was used to treat two patients with evidence of brain
disease progression and two patients with asymptomatic BM and
progressive disease in the extracranial sites. After 3 months of gefitinib,
all patients had a partial response in the brain and extracranial sites.
However, two patients discontinued gefitinib after 8 and 15 months due to
disease progression. To date, two patients remain on gefitinib after 6 and 11
months of treatment. Gefitinib was generally well tolerated, with only grade
1 and grade 2 skin toxicity in two patients and one patient, respectively.
While on gefitinib, all patients experienced symptom improvements and a
better quality of life. These preliminary findings suggest that gefitinib may
be effective in NSCLC patients with pretreated BM and that BM may not be
an exclusion criterion for future gefitinib studies. However, large clinical
trials are needed to validate these proposals.
Gefitinib (‘Iressa’, ZD1839) given in the ‘Iressa’
Expanded Access Programme in patients with
non-small-cell lung cancer
A Chioni
1, F Barbieri
2, E Baldini
1, C Orlandini
1, S Ricci
1
and PF Conte
2
1Ciari University Hospital, Pisa, Italy;
2Policlinico University
Hospital, Pisa, Italy
A total of 74 patients with advanced non-small-cell lung cancer (NSCLC),
who had failed to respond to one or more previous chemotherapy regimens
and were ineligible for further treatment, received gefitinib (‘Iressa’,
ZD1839) 250mgday
 1 monotherapy as part of the ‘Iressa’ Expanded Access
Programme. The demography of this patient group comprised a
male:female ratio of 56:18, with a median (range) age of 65 (43–81)
years. Tumour types included squamous-cell carcinoma (27 patients),
adenocarcinoma (18 patients), bronchioloalveolar carcinoma (seven
patients), undifferentiated large cells (10 patients) and unspecified NSCLC
(12 patients). The median (range) performance status (PS) was 1 (0–3) and
53% of patients had previously failed to respond to a second-line, taxane-
containing regimen. Of the randomised patients, 97% were evaluable and
no clinical remission was observed. Disease progressed in 47 patients,
although disease stabilised in 25 patients. Median progression-free survival
and overall survival were 11.6 weeks (range 10 days to 80 weeks) and 18.4
weeks (range 10 days to 86.6 weeks), respectively. Survival rates were found
to differ significantly depending on PS prior to treatment (PS 0–1 vs PS
2–3; Po0.0001). In general, gefitinib was well tolerated, with the most
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1 cutaneous toxicity in 8%. Two patients had grade 3 diarrhoea and one
patient had grade 3 diarrhoea plus grade 3 cutaneous toxicity. This case
series demonstrates that gefitinib therapy is well tolerated and results in
disease stabilisation in 34% of heavily pretreated patients at an advanced
stage of disease. In total, 11 patients continued to receive gefitinib
treatment.
Gefitinib (‘Iressa’, ZD1839) in advanced non-small-cell
lung cancer patients progressed to chemotherapy
H Cortes-Funes
1, M Constenla Figueiras
2, S Martı ´n-
Algarra
3, P Salinas
4, B Massutı ´5, P Gasco ´n
6 and R Rosell
7
1Hospital Universitario 12 de Octubre, Madrid, Spain;
2Hospital
Pontevedra, Pontevedra, Spain;
3Clı ´nica Universitaria, Navarra,
Spain;
4MD Anderson International Cancer Center, Madrid, Spain;
5Hospital General, Alicante, Spain;
6Hospital Clı ´nico, Barcelona,
Spain;
7Hospital German Trias i Pujol, Barcelona, Spain
We have retrospectively assessed the safety profile and antitumour activity
of 250mgday
 1 gefitinib (‘Iressa’, ZD1839) in 113 pretreated patients with
advanced non-small-cell lung cancer (NSCLC) treated as part of the ‘Iressa’
Expanded Access Programme. Patient demography is as follows: male:-
female 89:24; median age 61 (range 36–83) years; stage I-IIa/IIIb-IV, 30/
70%; number of tumour sites 1/2/3, 43/27/31%; adenocarcinoma 41%,
squamous-cell carcinoma 40%, large-cell carcinoma 15%; number of
prior chemotherapy regimens 1/2/X3, 21/49/30%; Eastern Cooperative
Oncology Group performance status 0–1/2–3/4, 73/25/1%. The median
duration of treatment was 81 (range 29–457) days. Ninety-one patients
were evaluable for response and three partial responses were observed
(3.2%). Disease control rate (response plus stable disease) was 39.8%
(95% confidence interval [CI] 29.9, 49.8) and was unaffected by histology,
stage at diagnosis or the number of prior chemotherapy regimens.
Median time to progression was 3.5 months (95% CI 3.2, 3.8) and median
survival was 6.7 months (95% CI 4.7, 8.6). Skin toxicity, the most frequent
adverse event, occurred in 42.5% of patients (3.5% grade 3/4). Other
toxicities included diarrhoea (21.2%; 0.9% grade 3/4), asthenia (20.4%;
5.3% grade 3/4), nausea and vomiting (10.6%; 0.9% grade 3/4), anorexia
(9.7%; 3.5% grade 3/4), neurological toxicity (9.7%; 1.8% grade 3/4) and
pulmonary toxicity (0.9%; 0.9% grade 3/4). No gefitinib-related deaths were
observed. These data confirm the acceptable safety profile and antitumour
activity of gefitinib therapy in pretreated patients with NSCLC. While the
response rate was low, a promising rate of disease control has been
observed.
Correlation between epidermal growth factor receptor
expression and tumour response in patients with
advanced non-small-cell lung cancer treated with
gefitinib (‘Iressa’, ZD1839)
F de Braud
1,2, C Noberasco
1,2, G Curigliano
1,2,
M De Pas
1,2, L Dodaro
1,2, S Manzoni
1,2, A Milani
1,2,
A Rocca
1,2, F Ferrucci
1,2, G Ferretti
1,2 and G Pelosi
1,2
1European Institute of Oncology, Milan, Italy; and
2Regina Elena
Cancer Institute, Rome, Italy
From March 2001 to February 2002, 79 patients with previously treated,
locally advanced or metastatic non-small-cell lung cancer (NSCLC) began
oral gefitinib (‘Iressa’, ZD1839) 250mgday
 1 therapy. Their characteristics
were: male/female, 51/28; median (range) age, 56 (31–77) years;
adenocarcinoma (51 patients), squamous-cell carcinoma (14 patients),
bronchioloalveolar (three patients), undifferentiated (four patients);
median (range) number of prior chemotherapy regimens, 2 (1–6). The
most common metastatic sites were lung (72 patients), lymph nodes (44
patients), bone (25 patients), liver (18 patients) and brain (11 patients). A
total of 14 patients were not assessable (three ceased treatment, seven died
and four had not received treatment for a sufficiently long period). Of 65
patients evaluable for response, five (8%) had a partial response (PR) and
19 (29%) had stable disease (SD). Median durations of PR and SD were 7
and 4 months, respectively. Gefitinib was generally well tolerated. The most
common adverse events (67 patients) were mild (National Cancer Institute
Common Toxicity Criteria grade 1/2) skin reactions (30%), diarrhoea (9%)
and nausea (4%). Grade 3/4 skin reactions occurred in 2% of patients.
Immunohistochemical detection of epidermal growth factor receptor
(EGFR) expression was studied in patients with PR or SD (group A) and
nonresponders (group B). EGFR expression (% cells) was mean7s.d.
(range) 69.5727.0 (20–95) in group A (11 patients) and 47.1743.4 (0–95)
in group B (12 patients); P¼0.241. The experiences of these patients with
advanced NSCLC demonstrate gefitinib to be effective for people who have
received prior chemotherapy. All responders were EGFR-positive in X20%
of cells (mean 69.54%). According to these preliminary immunohisto-
chemical data, EGFR status should be determined.
Impact of gefitinib (‘Iressa’, ZD1839) in a patient with
brain metastasis from non-small-cell lung cancer
J de la Cruz
1 and N Giacomi
1 [a]
1Centro Oncologico de Excelencia, La Plata, Buenos Aires,
Argentina
In June 2000, a 56-year-old female nonsmoker was diagnosed with a lung
adenocarcinoma (stage III, T3N2M0). Thoracic surgery was performed with
a right lobectomy. Chemotherapy with paclitaxelþcarboplatin (six cycles)
and lung radiotherapy achieved a complete response. During follow-up in
November 2001, the patient showed loss of strength in her hands and an
MRI scan showed a sole image in the right parietal region. Surgery was
performed with posterior whole-brain radiotherapy, followed by three
cycles of treatment with docetaxel. In December 2001, the patient suffered
pleural effusion and, in April 2002, hepatic nodules were revealed by CT
scan and hepatic ultrasound. After 1 month of treatment with gefitinib
(‘Iressa’, ZD1839) 250mgday
 1 the patient achieved a great benefit in
symptom relief (70% reduction in pain and dyspnoea), weight increase and
a performance status of 1. She was able to return to normal life and
analgesic use was drastically reduced. Imaging diagnosis until March 2003
showed stable disease; furthermore, the patient continued to be free from
central nervous system (CNS) tumours. In April 2003 the response time was
411 months and the overall survival was 434 months. Gefitinib was well
tolerated, with the adverse events comprising skin rash (grade 2) and
myalgia (grade 1). Treatment with gefitinib in this patient has demon-
strated that a clear benefit in clinical response can be achieved even
following heavy pretreatment with cytotoxic agents and radiotherapy. We
conclude that it is possible to achieve a long duration of response and
improvement of symptoms in patients with CNS metastases treated with
gefitinib.
Prolonged survival and clinical benefits with gefitinib
(‘Iressa’, ZD1839) in a patient with brain metastasis
from non-small-cell lung cancer
J de la Cruz
1 and N Giacomi
1 [b]
1Centro Oncologico de Excelencia, La Plata, Buenos Aires,
Argentina
A 56-year-old male patient with a 30-year history of smoking presented
with cough and thoracic pain in July 1998. He was diagnosed with
locoregional (stage IIIb) epidermoid lung carcinoma (50   60-mm lump
in the upper right lobule with mediastinal adenopathies), concomitant
hypertension and chronic obstructive pulmonary disease. He received
treatment as follows: paclitaxelþcarboplatin (six cycles); docetaxel (six
cycles); and gemcitabine (three cycles)þlung radiotherapy, all of which
resulted in partial responses. In July 2001, he presented with instability
while walking, an MRI scan showed a sole 2.5-cm metastasis in the
cerebellum. Surgery was performed followed by whole-brain radiotherapy
and three cycles of gemcitabine treatment. In September 2001, progression
at the pulmonary and osseous level was apparent, the patient had a
performance status (PS) of 3. Gefitinib (‘Iressa’, ZD1839) 250mgday
 1 was
administered for 12 months. Imaging diagnosis at 3, 6 and 9 months
showed stable disease and he remained free from tumours in the central
nervous system (CNS). Improvements in dyspnoea (70%), pain (70%),
cough (50%), quality of life (75%), lifestyle (100%) and PS (1) were seen
within 30 days. The patient gained weight and returned to full-time work.
Tolerability was good, with skin rash (grade 2), myalgia (grade 1) and slight
vision impairment. The patient’s overall survival was 57 months. This
illustrates that gefitinib treatment produces benefits in clinical response
even in patients with poor PS who have already been heavily pretreated.
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patients with CNS metastasis, for whom no other treatment is currently
available.
Analysis of the efficacy and tolerability of gefitinib
(‘Iressa’, ZD1839) in previously treated patients with
non-small-cell lung cancer enrolled in the ‘Iressa’
Expanded Access Programme
K de Leeuw
1, D Schallier
1, E Sermijn
1, C Fontaine
1,
B Neyns
1, I Samijn
1 and J de Gre `ve
1
1Oncology Centre AstraZeneca-VUB, Belgium
In this retrospective analysis, the efficacy and tolerability of gefitinib
(‘Iressa’, ZD1839) monotherapy was evaluated in 28 patients with stage IV
non-small-cell lung cancer (NSCLC) who had failed previous treatments,
including chemotherapy. Patients were treated with oral gefitinib
250mgday
 1 for a median duration of 43.5 (range 7–256) days. Gefitinib
was given as second-line therapy to seven patients, as third-line therapy to
16 patients and as fourth-line therapy to five patients. Median overall
survival was 84.5 (range 7–256) days. Eight patients experienced stable
disease for a median duration of 201 (range 59–256þ) days. No objective
responses were observed. Gefitinib was well tolerated with no grade 3 or 4
toxicities reported. Eight patients developed mild-to-moderate skin rash
and eight patients reported mild-to-moderate diarrhoea. In our heavily
pretreated patients with NSCLC, gefitinib was well tolerated and produced
long-term stable disease in a significant proportion of patients. Treatment
with gefitinib should therefore be an option in NSCLC patients who have
exhausted, or are too frail to support, known active treatments. Further
research into the molecular determinants of response to gefitinib is
warranted.
Efficacy of gefitinib (‘Iressa’, ZD1839) in non-small-cell
lung cancer metastatic to the brain
E Diaz-Canto ´n
1
1Centro de Educacion Medica e Investigaciones Clinicas, Buenos
Aires, Argentina
In January 2000, a 79-year-old female patient with metastatic non-small-cell
lung cancer received radiotherapy to bone and brain metastases followed
by 3-weekly, first-line, palliative chemotherapy with paclitaxel
(200mgm
 2) and carboplatin (AUC 6) given on Day 1. The patient
experienced severe intolerance to chemotherapy within two cycles.
Chemotherapy was discontinued due to toxicity and the patient was
included in the ‘Iressa’ Expanded Access Programme on compassionate
grounds. After 3 months, a complete response (CR) of short duration (1
month) was documented in the brain. Gefitinib (‘Iressa’, ZD1839)
250mgday
 1 was well tolerated with no deterioration in performance
status. A mild cutaneous acneiform rash was the only adverse event. The
patient died 4 months after beginning gefitinib therapy due to nonspecific
alveolitis. While the CR could be explained by the delayed effect of
radiotherapy prior to gefitinib treatment, this would be unlikely consider-
ing that there were no significant changes in two CT brain scans following
brain irradiation in January and March 2002. Additionally, 2 weeks after
starting gefitinib, serum alkaline phosphatase levels and pain in her
thoracic and lumbar spine increased and a blastic reaction of the spine was
documented (CT scan); these could have been related to progressive disease
in the bone in the context of a mixed response. In conclusion, gefitinib
therapy, which was well tolerated, resulted in a CR in the brain of short
duration. Further research is required to better understand the activity of
this drug in metastatic disease on the central nervous system.
A 60-year-old man with metastatic non-small-cell lung
cancer at diagnosis survived 20 months
B Dieriks
1, D Galdermans
1, L Bedert
1, H Slabbynck
1 and
D Coolen
1
1Algemeen Ziekenhuis, Middelheim, Belgium
A 60-year-old man, who had stopped smoking 10 years earlier, was
diagnosed with stage IV non-small-cell lung cancer in July 2001.
Metastatic sites included lung, liver and brain and his WHO performance
status was 0. The patient initially received six cycles of combination
therapy with vinorelbine (25mgm
 2) and gemcitabine (1000mgm
 2),
both given on Days 1 and 8 of a 3-weekly cycle (August–December
2001), and demonstrated a partial response. Subsequently, the patient
received 4 cycles of docetaxel (75mgm
 2 every 3 weeks, April–June
2002) but did not respond to this second-line therapy. At this point, he was
in a very bad condition, with dyspnoea and cough due to lung metastasis,
and confusion and headache due to brain metastasis. Oral gefitinib
(‘Iressa’, ZD1839) 250mgday
 1 was given for a period of 6 months (June–
December 2002), during which time the patient experienced a partial
response with dramatic radiological improvement. A skin reaction was
reported, which was treated for 10 days with the antibiotic doxycycline
(100mgday
 1). Disease-specific symptoms of dyspnoea and cough
improved within 10 days of receiving gefitinib and had disappeared after
2 weeks of treatment, and the improvement in the patient’s quality of life
enabled him to return to his job for more than 6 months. The patient died
in February 2003, having spent just the last week of his life in a palliative
care unit.
Clinically meaningful response to the epidermal growth
factor receptor tyrosine kinase inhibitor gefitinib
(‘Iressa’, ZD1839) in non-small-cell lung cancer
A Gelibter
1, A Ceribelli
1, M Milella
1, M Mottolese
1,
A Vocaturo
1 and F Cognetti
1
1Regina Elena Cancer Institute, Rome, Italy
A 39-year-old man, with no history of smoking, presented in June 2000 with
poorly differentiated bronchioloalveolar adenocarcinoma with high ex-
pression of epidermal growth factor receptor (EGFR) detected immuno-
histochemically, and amplification of the EGFR gene detected by
chromogenic in situ hybridisation. Treatment with six cycles of cisplatin
and gemcitabine achieved a partial response that lasted 7 months.
Carboplatin and paclitaxel were given but after three cycles the disease
progressed. Vinorelbine was started and resulted in stable disease lasting 5
months. In October 2001 the patient’s Eastern Cooperative Oncology Group
performance status (PS) was 2 and he was heavily symptomatic (cough,
dyspnoea, fever and severe restrictive pulmonary deficit, which required
treatment with corticosteroids and oxygen). A chest CT scan showed
metastatic disease. Oral gefitinib (‘Iressa’, ZD1839) 250mgday
 1 was
started. Within 2 weeks his dyspnoea and fever resolved and by week 4 his
cough had abated. After 8 weeks his PS was 0 and by week 12 he required
no supportive care. Pulmonary function improved steadily at 7 and 17
weeks and a chest CT scan, performed at 10 weeks, showed almost a
complete resolution of the clinical picture. Gefitinib was well tolerated,
although a mild acneiform rash was observed at week 2, which
spontaneously decreased by Week 7. The patient has received gefitinib
for 52 weeks and remission maintained up to 32 weeks. In conclusion, we
consider that all patients with advanced or recurrent non-small-cell lung
cancer, irrespective of their disease histology or EGFR status, should be
considered for inclusion into clinical trials of signal transduction
inhibitors.
A case of diffuse interstitial pneumonitis in a patient
with stage IV non-small-cell lung cancer receiving
gefitinib (‘Iressa’, ZD1839) treatment
R Gervais
1, J Chasles
1, A Rivie `re
1and J-J Michels
1
1Centre Franc¸ois Baclesse, Caen, France
This case report describes the treatment of a female smoker (aged 45 years)
who was diagnosed with stage IIIb non-small-cell lung cancer in August
2001. She had no coexisting illnesses and no other lung complications.
Initially she was treated with cisplatin and vinorelbine (three cycles), with
an outcome of partial response, and this was followed with thoracic
radiotherapy. In April 2002 the disease progressed to stage IV, with
metastases in the adrenal glands and liver. Second-line docetaxel (six
cycles) commenced in October 2002, which initially stabilised the disease
but eventually further disease progression was observed. Following these
relapses after two chemotherapy regimens and radiotherapy, treatment
with oral gefitinib (‘Iressa’, ZD1839) 250mgday
 1 was begun. However, a
diffuse interstitial pneumonitis occurred in the first 2 weeks of treatment.
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patient died 10 days after the interstitial pneumonitis was diagnosed. The
total duration of gefitinib treatment was 25 days.
Gefitinib (‘Iressa’, ZD1839) in special patient
populations (elderly X70 years or performance status
X2) with advanced non-small-cell lung cancer: a case
series report from the ‘Iressa’ Expanded Access
Programme
C Gridelli
1, P Maione
1, A Rossi
1, C Guerriero
1,
ML Barzelloni
1 and C Ferrara
1 [a]
1SG Moscati Hospital, Avellino, Italy
A total of 59 patients with advanced non-small-cell lung cancer (NSCLC)
were entered into the ‘Iressa’ Expanded Access Programme and given
gefitinib (‘Iressa’, ZD1839) 250mgday
 1. Patients were either elderly (X70
years old) or had performance status (PS) (Eastern Cooperative Oncology
Group) X2. Elderly group consisted of 18 patients (17 male, one female),
median age 73.5 years, with stage IIIb (three patients) or IV (15 patients)
disease and PS 1/2/3 in 4/11/3 patients. The disease histologies were
squamous-cell carcinoma (SCC) (10 patients), adenocarcinoma (six
patients), bronchioloalveolar carcinoma (one patient) and undefined
NSCLC (one patient). Gefitinib was received as first-line (one patient),
second-line (seven patients) or Xthird-line treatment (10 patients). All
patients were evaluable. No objective responses were seen and stable
disease (SD) was achieved in one patient. The most frequent adverse events
were grade 1 and 2 skin changes in four patients and one patient,
respectively, and grade 1 diarrhoea in three patients. Unfit patient group
consisted of 41 patients (26 male, 15 female), median age 60 years, with
stage IIIb (four patients) or IV (37 patients) disease and PS 2/3 in 29/12
patients. Their disease histologies were SCC (17 patients), adenocarcinoma
(21 patients) and undefined NSCLC (three patients). Patients received
gefitinib as first-line (one patient), second-line (16 patients) or third-line
(24 patients) treatment. From 39 evaluable patients, two patients with
adenocarcinoma reported a partial response, four patients had SD and six
patients had controlled disease. The most frequent adverse events were
grade 1 diarrhoea in two patients and grade 2 hypertransaminasaemia in
one patient. These data suggest that gefitinib is well tolerated in elderly or
unfit patients with advanced NSCLC.
Gefitinib (‘Iressa’, ZD1839) in heavily pretreated non-
small-cell lung cancer patients: a case series report from
the ‘Iressa’ Expanded Access Programme
C Gridelli
1, A Rossi
1, P Maione
1, L Musto
1, F Del Gaizo
1
and G Airoma
1 [b]
1SG Moscati Hospital, Avellino, Italy
Gefitinib (‘Iressa’, ZD1839) 250mgday
 1 was administered as a single
agent in the ‘Iressa’ Expanded Access Programme to 83 nonhospitalised
patients (aged 33–80 years) with advanced non-small-cell lung cancer
(NSCLC). Patients received gefitinib as first-line (two patients), second-line
(35 patients) and Xthird-line (46 patients) treatment. The cohort consisted
of 64 male and 19 female patients (median age 61 years) with stage IIIb (11
patients) and stage IV (72 patients) disease, and performance status
(Eastern Cooperative Oncology Group) 0/1/2/3 in 4/24/40/15 patients.
The disease histologies were adenocarcinoma (39 patients), squamous-cell
carcinoma (35 patients), bronchioloalveolar carcinoma (2 patients)
and undefined NSCLC (7 patients). To date, 71 patients are evaluable
for response and tolerability. Objective responses were reported in four
of the evaluable patients (complete response, one male patient;
partial response, three female patients). The disease histology of all
responders was adenocarcinoma. Epidermal growth factor receptor (EGFR)
expression data were available for two responders; both were EGFR
negative. Stable disease and disease control were seen in 12 and 16 of
the evaluable patients, respectively. The most frequent adverse events
were: grade 1 and 2 skin changes (six and two patients, respectively);
grade 1 diarrhoea (seven patients); grade 2 hypertransaminasaemia (one
patient); and grade 1 epistaxis (one patient). Our data confirm the activity
and tolerability of gefitinib in heavily pretreated patients with advanced
NSCLC.
Gefitinib (‘Iressa’, ZD1839), an option for patients with
recurrent non-small-cell lung cancer who have failed
chemotherapy: a case series report of 92 patients
A Haringhuizen
1, HFR Vaessen
1, P Baas
1 and
N van Zandwijk
1
1The Netherlands Cancer Institute, Amsterdam, The Netherlands
Between May 2001 and September 2002, 92 patients with recurrent,
advanced non-small-cell lung cancer (NSCLC) received 250mgday
 1
gefitinib (‘Iressa’, ZD1839) in the ‘Iressa’ Expanded Access Programme.
Patients were aged 33–76 years; 33% had performance status (WHO) X2;
86% had stage IV disease and 14% had stage III; 62% (57 patients) had
adenocarcinoma (including six patients with bronchioloalveolar carcino-
ma). In all, 62% of patients had received first-line chemotherapy, 30.5% had
received 4first-line chemotherapy and 7.5% were chemonaive. Median
treatment duration was 10.7 (range 0.4–75.3) weeks, although 26 patients
continue to receive gefitinib at the time of reporting. Objective responses
(8.7%; one complete, seven partial) were observed in patients with
adenocarcinoma and the median duration of response was 5.0 (range
1.20–15.8) months. In total, 37% of patients had stable disease, giving an
overall disease-control rate of 45.7%. Median survival was 5.4 (range 0.21–
18.4) months and 1-year survival approached 10%, although this may
change when data are updated. A total of 6.5% of patients had progression-
free survival X6 months. Gefitinib was well tolerated and most side effects
were mild. The most frequent were grade 1/2 diarrhoea and skin rash, seen
in 36.2 and 22.9% of patients, respectively. In all, 26% of patients received
palliative radiotherapy during treatment without additional toxicity. One
patient had radiological signs of interstitial lung disease (ILD), without
symptoms. Gefitinib treatment was maintained and the patient attained a
partial response lasting 414 months, with the ILD resolving sponta-
neously. These data confirm the activity and good tolerability of gefitinib in
unselected NSCLC patients who failed previous therapy.
Gefitinib (‘Iressa’, ZD1839) for patients with advanced
non-small-cell lung cancer treated in the ‘Iressa’ Ex-
panded Access Programme at a single institution in Brazil
A Katz
1, O Smaletz
1, SD Simon
1, GC Rene
1, PM Hoff
1 and
J Tabacof
1
1Hospital Israelita Albert Einstein, Centro Paulista de Oncologia,
Sa ˜o Paulo, Brazil
A total of 26 patients (16 male, 10 female) aged 38–84 years (median 67
years) with non-small-cell lung cancer (NSCLC) (stage IIIb/IV 1/25)
received oral gefitinib (‘Iressa’, ZD1839) 250mgday
 1 until progression or
unacceptable toxicity developed. Their median performance status (Eastern
Cooperative Oncology Group) was 1. In all, 25 patients had previously
received a platinum and taxane based-regimen, and one patient was
chemonaive. The median treatment duration with gefitinib was 50 (range
1–635) days. Three patients who died within 7 days of treatment initiation
were not evaluated for response. Of the remaining patients, all of whom
received treatment for at least 4 weeks, 19% (95% CI, 4–46%) had a partial
response and 52% (95% CI, 25–75%) had disease stabilisation. The median
time to progression was 1.7 (range 0.1–21.2) months and median survival
was 3.2 (range 1.7–26.2þ) months. A significant proportion of patients
experienced prolonged clinical benefit: 12 patients survived for more than 6
months, seven patients for more than 9 months and three patients for more
than 1 year. Seven patients continue to be treated with gefitinib. The most
frequently reported toxicities were grade 1 skin rash (16%) and grade 1/2
diarrhoea (42/11%). No grade 3/4 toxicities were seen. In conclusion, our
results with gefitinib in this heavily treated population is comparable with
other studies in patients with advanced NSCLC; gefitinib has a significant
activity with acceptable toxicity.
Treatment of non-small-cell lung cancer in the ‘Iressa’
Expanded Access Programme: experience of the medical
university of Gdan ´sk
A Kowalczyk
1, R Dziadziuszko
1, E Szutowicz-Zielinska
1,A
Badzio
1 and J Jassem
1
1Medical University of Gdan ´sk, Poland
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pretreated non-small-cell lung cancer (NSCLC) received gefitinib (‘Iressa’,
ZD1839) 250mgday
 1 in the ‘Iressa’ Expanded Access Programme. Of
these, 32 patients were evaluable for objective and symptomatic response
and survival, comprising 24 men (75%) and eight women (25%) (mean age
60 (range 30–79) years). There were 20 cases (63%) of squamous-cell
carcinoma, eight (25%) adenocarcinoma and four (12%) other NSCLC. In
all, 12 patients (38%) had previously undergone pulmonary resection. In
total, 26 patients (81%) had received first-line chemotherapy with a median
4 (range 1–8) cycles. Second-line chemotherapy was administered to 11
patients (34%) and third-line chemotherapy to 1 (3%). Prior radical or
postoperative radiotherapy was applied in four patients (13%) and
palliative radiotherapy in 16 (50%). Gefitinib treatment was well tolerated,
with acne-like skin changes and rash occurring most frequently (12
patients, 38%). Symptomatic improvement was achieved in six patients
(19%) and objective confirmed response in two (6%). Both responders were
nonsmoking women (42 and 39 years) who experienced skin complications
attributed to gefitinib. Response duration was 7 and 4þ months. Durable
disease stabilisation (46 months) was observed in one patient. The median
survival was 7 (95% confidence interval [CI] 3–10) months and 1-year
survival probability was 31% (95% CI 12–51%). Although objective
response was rare, the response duration and symptomatic improvement
following gefitinib treatment was of significant benefit. Responses achieved
in young, nonsmoking women are intriguing but in keeping with previous
observations. Further studies including clinical and biological prognostic
factors are warranted.
A case report of a non-small-cell lung cancer patient
with brain metastases
DM Kowalski
1, K Zajda
1 and M Krzakowski
1
1M Sklodowska-Curie Memorial Cancer Centre, Warsaw, Poland
A 58-year-old male patient was diagnosed with stage IV non-small-cell
lung cancer (NSCLC) and brain metastases in May 2001. He had a
Karnofsky performance status of 80%. Initial treatment comprised
carboplatin and teniposide (four cycles) with whole-brain irradiation
(30Gy). Palliative radiotherapy was also given to the chest. The patient had
a partial response, which was maintained for 16 months. Second-line
cisplatin-based chemotherapy, given on disease progression, resulted in
stable disease. He subsequently received oral gefitinib (‘Iressa’, ZD1839)
250mgday
 1 for 3 months as part of the ‘Iressa’ Expanded Access
Programme, with disease stabilisation and improvement in quality of life
and lifestyle. Gefitinib was well tolerated. Further chemotherapy has
comprised carboplatin and gemcitabine. As of May 2003, the patient was
still alive 24 months after diagnosis of brain metastases. This case illustrates
that gefitinib is effective as third-line therapy for patients with metastatic
NSCLC.
Complete response of brain metastases from lung
adenocarcinoma with gefitinib (‘Iressa’, ZD1839)
P Maione
1, L Musto
1, A Rossi
1, D Nicolella
1, C Lombardi
1
and C Gridelli
1
1SG Moscati Hospital, Avellino, Italy
In January 2001, a 51-year-old woman was diagnosed with lung
adenocarcinoma and bone metastases. She had no smoking history or
comorbidities. The patient was treated with six cycles of cispla-
tinþvinorelbine chemotherapy up to June 2001 and achieved a partial
response. In December, she developed multiple brain metastases and was
treated with palliative radiotherapy, which stabilised her brain disease.
From January to June 2002, six cycles of gemcitabine were administered as
second-line chemotherapy; however, the disease in her lungs and bone
progressed. She was given palliative radiotherapy on thoracic (T8) vertebra,
which improved her pain. In July 2002, the patient was referred to our
hospital with an Eastern Cooperative Oncology Group performance status
(PS) of 3, her serum level of carcinoembryonic antigen (CEA) was
1400ngml
 1 and her epidermal growth factor receptor expression status
was unknown. She was enrolled into the ‘Iressa’ Expanded Access
Programme as an outpatient and commenced treatment with oral gefitinib
(‘Iressa’, ZD1839) 250mgday
 1. In October 2002, a CT scan of her brain,
chest and abdomen showed a complete response for brain metastases,
minimal response for lung disease and stabilisation of bone disease. CEA
serum level decreased to 104ngml
 1 and both her symptoms and PS (1)
improved. These data were confirmed in January 2003, when a further
decrease of lung lesion tissue resulted in the patient achieving an
overall partial response to gefitinib treatment. As of April 2003, the patient
is continuing gefitinib and has not experienced any toxicity during
treatment.
Impact of third-line gefitinib (‘Iressa’, ZD1839) therapy
on patients with advanced non-small-cell lung cancer
who had failed prior platinum- and/or docetaxel-based
regimens: case series
A Mancuso
1, O Martelli
1, MR Migliorino
1, R Di Salvia
1 and
F De Marinis
1
1Forlanini Hospital, Rome, Italy
Patients with non-small-cell lung cancer (NSCLC) pretreated with
two to three standard chemotherapy regimens have a median overall
survival time of 4 months (Massarelli et al. (2003) Lung Cancer 39: 55).
Gefitinib (‘Iressa’, ZD1839), an EGFR-TKI (epidermal growth factor
receptor tyrosine kinase inhibitor), has recently shown favourable
antitumour activity (30%) and symptom improvement (40%) in patients
with NSCLC (Fukuoka et al. (2003) J Clin Oncol 21: 2237–2246; Kris et al.
(2002) Proc Am Soc Clin Oncol 21: 292a). The efficacy of third-line gefitinib
was analysed using tumour response rates, time to third progression
(TTTP), time to death (TTD) and changes in Karnofsky performance status
(PS). A total of 32 patients who had failed two previous chemotherapy
regimens (median age 64 years; M/F, 69/31%; PS 1/2/3, 50/44/6%; locally
advanced/metastatic disease, 69/31%) received 250mgday
 1 oral gefitinib.
Disease control was observed in 20 out of 24 (83%) evaluable patients; two
(8%) had partial remissions (both women with histologically confirmed
adenocarcinoma) and 18 had stable disease. The median overall TTTP and
TTD for 13 evaluable patients were 4 and 6 months, respectively. A positive
correlation was observed between the related time to progression for
second- and third-line treatment with docetaxel and gefitinib, respectively;
81% (13 out of 16) of the patients who progressed X4 months after starting
docetaxel had a TTTP of 44 months using gefitinib. PS improved rapidly
(within 15 days) in 10 out of 32 patients (31%), allowing a reduction in
analgesic use. Most drug-related adverse events were mild and reversible;
treatment was discontinued in two patients (8%) with grade 2/3 diarrhoea
and skin rash.
Gefitinib (‘Iressa’, ZD1839) in heavily pretreated
patients with metastatic non-small-cell lung cancer
S Martı ´n-Algarra
1, A Gurpide
1 and JM Lopez-Picazo
1
1Servicio Oncologia Medica, Clinica Universitaria Navarra, Pam-
plona, Spain
In October 2001, a 68-year-old woman was diagnosed with metastatic
adenocarcinoma of the lung. From October 2001 to April 2002, the patient
was treated with 4-week cycles of cisplatin, paclitaxel and gemcitabine, and
achieved stable disease. However, 1 month after stopping treatment, an
MRI scan showed a new brain lesion and bone metastases and a CT scan
showed local progression. Treatment with oral gefitinib (‘Iressa’, ZD1839)
250mgday
 1 began in May 2002 as part of the ‘Iressa’ Expanded Access
Programme. In June 2002, the patient underwent further imaging studies
that showed a partial response in the brain and lung lesions. To date, 12
months after gefitinib treatment started, the patient has stable systemic
disease, symptoms are improved and gefitinib continues to be well
tolerated with no adverse events.
Rapid symptom improvement in a patient with non-
small-cell lung cancer given gefitinib (‘Iressa’, ZD1839)
JL Martı ´nez
1
1Hospital Brita ´nico, Buenos Aires, Argentina
A 60-year-old female patient who had smoked for 20 years was diagnosed
in July 2002 with stage IV non-small-cell lung cancer with multiple brain
metastases. Her performance status at diagnosis was 1. She received
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best response of stable disease, but chemotherapy was discontinued due to
a high level of toxicity. The patient started oral gefitinib (‘Iressa’, ZD1839)
250mgday
 1 on 5 March 2003, concomitantly with prednisolone and
fenytoine, as part of the ‘Iressa’ Expanded Access Programme. Her only
symptom, dry cough, disappeared after the first week of treatment.
Performance status improved from 1 to 0 after 1 month. On 8 April 2003,
an MRI scan showed stable disease and on 6 May 2003 a chest X-ray
showed complete response in the primary lesion. To date, the patient is still
receiving gefitinib without any adverse reaction, continues to have
improved symptoms and quality of life, and is waiting for a new CT scan
to confirm the complete response.
Response and symptom improvement with gefitinib
(‘Iressa’, ZD1839) 250mgday
 1 in a patient with poor
performance status
T Overbeck
1 and F Griesinger
1
1University of Go ¨ttingen, Go ¨ttingen, Germany
A 62-year-old female patient with non-small-cell lung cancer (adenocarci-
noma/bronchoalveolar carcinoma (BAC)) had previously undergone
surgery and chemotherapy (four cycles of docetaxel/carbopla-
tinþerythropoietinþgranulocyte colony-stimulating factor). After 14
months without treatment, bronchoscopy showed an exophytic tumour
with B50% stenosis of the right main bronchus. A chest X-ray (July 2002)
revealed polytopic pulmonary nodules. The patient had a performance
status (Eastern Cooperative Oncology Group) of 2–3. In July 2002, she
began oral gefitinib (‘Iressa’, ZD1839) 250mgday
 1 in the ‘Iressa’
Expanded Access Programme. A chest X-ray in October 2002 revealed
B50% size reduction of the multiple pulmonary nodules and a
bronchoscopy showed endobronchial tumour regression. The dyspnoea
reported before therapy improved after 4 weeks of gefitinib, oral steroids
and terbutaline sulphate, with further improvement after 8 weeks. After 4
weeks of gefitinib the patient reported skin itching. In November 2002 the
patient was hospitalised with sudden symptoms, including cough,
dyspnoea and light fever, and vital capacity (VC) was reduced to B50%.
Endoscopic signs were similar to acute bronchitis. Symptoms improved
with antibiotics/prednisolone and gefitinib was discontinued for B1
month. The episode was interpreted as interstitial pneumonia (IP) due to
medication with gefitinib. In January 2003 (after resolution of clinical signs
of IP, VC B82%) gefitinib and corticosteroids were restarted because of
progressive BAC. Therapy was accompanied by nausea, vomiting, fatigue
and mucositis. Again gefitinib improved dyspnoea. In April 2003 she
presented with deep vein thrombosis. This patient had a significant and
subjective response to gefitinib. The clinical course was complicated by IP,
which was successfully treated. Rechallenge of the tumour by gefitinib
resulted in significant symptom improvement.
Gefitinib (‘Iressa’, ZD1839) produces disease control
and significant improvement in symptoms in patients
with advanced non-small-cell lung cancer
AG Pallis
1, D Mavroudis
1, N Androulakis
1, J Souglakos
1,
C Kourousis
1, V Bozionelou
1, N Vardakis
1,
IG Vlachonikolis
2 and V Georgoulias
2
1University Hospital of Heraklion, Greece;
2School of Medicine,
University of Crete, Crete, Greece
A total of 31 patients (M/F, 27/4; median age 60 (range 43–65) years) with
advanced unresectable, progressive non-small-cell lung cancer (NSCLC)
(stage IIIb, 15 patients; stage IV, 16 patients), who had been treated with
X2 prior chemotherapy regimens, received gefitinib (‘Iressa’, ZD1839)
orally, 250mgday
 1 for a median duration of 8 (range 3–32) weeks. Four
patients were WHO performance status (PS) 0, 21 were PS 1 and 6 were PS
2. One patient achieved partial response and nine patients had stable
disease, producing a disease control rate of 10 out of 31 (32%). After a
median follow-up of 18 weeks, 12 patients were still alive. Median overall
survival (OS) was 23 (range 4–40) weeks, median duration of response was
11 (range 1–32) weeks and median time to progression (TTP) was 9 (range
3–31) weeks. There was no difference in OS according to histological type
(P¼0.4169), disease stage (P¼0.496) or number of prior treatments
(P¼0.979). There was a significant difference for TTP between patients
with PS 0–1 and those with PS 2 (11 (range 3–31þ) weeks vs 4 (range 3–
8) weeks; Po0.001) and for OS (median survival: 27 weeks vs 6 weeks;
Po0.001). Symptoms were significantly improved in 39% of patients after 6
weeks compared with baseline (Po0.001). Median time to symptom
improvement was 3 (range 2–4) weeks. The majority of adverse events
were grade 1/2 and included skin rash (58%), diarrhoea (28%) and nausea/
vomiting (19%). In these heavily pretreated patients with advanced NSCLC,
gefitinib was well tolerated and produced disease control and symptom
improvement.
Symptom improvement following gefitinib (‘Iressa’,
ZD1839) therapy in a pretreated patient with
non-small-cell lung cancer
N Pavlakis
1
1Royal North Shore Hospital, St Leonards, New South Wales,
Australia
In November 2001, a 42-year-old male smoker was diagnosed with non-
small-cell lung cancer following a 3-month history of cough, weight loss
and increasing shortness of breath. A CT scan revealed a mass in the left
lung and multiple pulmonary nodules. In addition, malignant cells were
detected in the left supraclavicular lymph node by fine needle aspiration
biopsy. In December 2001, the patient received combination chemotherapy
(cisplatin and gemcitabine) but presented with progressive disease after
two cycles. In February 2002 the patient was treated with docetaxel but after
six cycles disease progressed in the chest and spleen. Cerebral metastases
were diagnosed in June 2002, and treated with radiation therapy (20Gy in
five fractions). Following commencement of gefitinib (‘Iressa’, ZD1839)
250mgday
 1, in December 2002, dramatic symptom improvement was
observed, including improved performance status to 1. Furthermore, extra-
cranial disease was stable, although progression of cerebral lesions
occurred. Gefitinib was generally well tolerated; however, the patient did
report a facial skin rash. The patient continued to receive gefitinib therapy
during neurosurgical analysis of these symptomatic lesions. However,
gefitinib therapy was terminated in February 2003 when the patient was
diagnosed with progressive disease of the central nervous system, and
developed hydrocephalus and meningeal disease. In conclusion, gefitinib
treatment was effective in alleviating symptoms in this patient with brain
metastases.
An elderly patient with extensive non-small-cell lung
cancer was effectively treated with first-line gefitinib
(‘Iressa’, ZD1839) followed by combined chemotherapy
M Pesek
1 and B Eliasova
1
1Faculty Hospital, Plzen, Czech Republic
A 70-year-old nonsmoking female patient suffering from cough, chest pain,
fever and severe comorbidity was diagnosed with extensive stage IV
pulmonary adenocarcinoma after clinical investigation and video-assisted
thoracoscopic surgery. The disease had metastasised into both lungs,
mediastinal lymph nodes and vertebral column, and a left-sided malignant
pleural effusion was found. The patient refused the proposed combined
chemotherapy due to anxiety. She received oral gefitinib (‘Iressa’, ZD1839)
250mgday
 1 from 5 January to 19 March 2002. The best response was
stable disease lasting for 2 months, accompanied by remission of pleural
effusion and marked improvement of cough, dyspnoea and chest pain,
which occurred within 2 weeks of starting treatment. There were some side
effects, particularly nausea and diarrhoea which resolved with the help of
standard pharmacological therapy. After minimal radiological progression,
the patient agreed to combined chemotherapy. There were four cycles of
combination therapy, consisting of gemcitabine (650mgm
 2; Days 1 and
8), paclitaxel (65mgm
 2; Days 1, 8 and 15) and carboplatin (AUC 2; Days
1, 8 and 15). Cycles were repeated from Day 35. This therapy resulted in
partial tumour remission, documented by chest X-ray and Tc-99m
Sestamibi gammagraphy. Symptomatic improvement also occurred. More
than 18 months from the date of diagnosis, the patient is still alive, with
slowly progressing malignant disease. This case report documents the
feasibility of first-line gefitinib treatment in an elderly patient with severe
comorbidity. Moreover, subsequent combined chemotherapy resulted in
partial remission of the tumour.
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heavily pretreated patients with locally advanced or
metastatic non-small-cell lung cancer treated with
gefitinib (‘Iressa’, ZD1839)
V Petersen
1, P Grau
1, F Schneller
1 and C Peschel
1
13 Medizinische Klinik, Klinikum rechts der Isar, Munich, Germany
A total of 33 patients (30 patients with metastatic disease, three patients
with locally advanced disease; median age 62 years) with non-small-cell
lung cancer (NSCLC) previously treated with chemotherapy received oral
gefitinib (‘Iressa’, ZD1839) 250mgday
 1. Gefitinib was given as second-line
treatment in nine patients, third line in 16 patients, fourth line in five
patients and fifth line in three patients. Seven patients developed stable
disease (X24 weeks in two patients) and one patient had a partial response.
There was no correlation between response to chemotherapy and response
to gefitinib, although the two patients who developed stable disease for
X24 weeks received gefitinib as third-line therapy. In all, 11 patients
reported an improvement in symptoms after 1 week of treatment.
Improvements in quality of life, six patients; cough, three patients; pain,
one patient; and dyspnoea, two patients were observed. One patient
reported an improvement in appetite and an increase in body weight.
However, in the majority of patients, symptom control stopped after 6
weeks of treatment. Ten patients had no side effects with gefitinib. In total,
16 patients developed acne (grade 1/2, 14 patients; grade 3, one patient;
grade 4, one patient), seven patients developed dry skin, seven patients
reported diarrhoea (grade 1, six patients; grade 3, one patient) and one
patient developed hypertrichosis. In this heavily pretreated population with
locally advanced or metastatic NSCLC, gefitinib was effective and produced
rapid reduction in symptoms in over one-third of patients.
Efficacy of gefitinib (‘Iressa’, ZD1839) in a patient with
advanced non-small-cell lung cancer with metastatic
spread to the brain
L Petruzelka
1 and M Zemanova
1 [a]
1University Hospital, Charles University, Prague, Czech Republic
A 61-year-old female nonsmoker, who suffered from coronary artery
disease and chronic obstructive pulmonary disease, initially presented with
coughing, dyspnoea and weight loss. After she developed superior vena
cava syndrome in December 1998, examination revealed squamous-cell
carcinoma of the right upper lobe with mediastinal involvement and
mediastinal lymph node enlargement (stage IIIb). Between January and
May 1999, four cycles of cisplatin and vinorelbine were administered, plus
concurrent radiation with cycles 2–4. The patient had a partial response;
however, tolerability was poor, with febrile neutropenia and nephrotoxicity.
The first relapse occurred in April 2000, consisting of a brain lesion
(adenocarcinoma), which was resected. Despite whole-brain irradiation in
June 2000, a further lesion occurred in another location, which was resected
in November, with surgery performed in September 2001. In May 2002, a
chest X-ray showed disease progression and the patient complained of
cough, dyspnoea and weight loss. Owing to her poor tolerability of previous
chemotherapy and comorbid conditions, oral gefitinib (‘Iressa’, ZD1839)
250mgday
 1 therapy began in June 2002. A partial response was observed
in August and symptoms improved. Gefitinib was generally well tolerated
with minimal toxicity (mild acneiform dermatitis and sporadic episodes of
diarrhoea). In February 2003, the patient had stable disease and Eastern
Cooperative Oncology Group performance status 1. Gefitinib therapy was
durable and effective in preventing local recurrence following radical
chemoradiotherapy with no disease progression after 9 months of
treatment. Furthermore, 18 months after the last surgery, there has been
no disease recurrence in the brain.
Regression of metastatic non-small-cell lung cancer in a
chemonaive patient treated with gefitinib (‘Iressa’,
ZD1839)
L Petruzelka
1 and M Zemanova
1 [b]
1University Hospital, Charles University, Prague, Czech Republic
This case report describes the treatment of a 64-year-old male exsmoker
who was diagnosed with squamous-cell carcinoma in February 2002,
although a nodule in the right supraclavicular area had been palpable for
several months. This patient also had hypertension, obesity, diabetes
mellitus, dyslipoproteinaemia and chronic obstructive pulmonary disease.
Surgical resection was performed in February 2002, including nonradical
removal of the supraclavicular lymph nodes. Staging procedures identified
a possible primary tumour in the right upper lobe, in addition to the
supraclavicular involvement, and multiple metastatic bone lesions (stage
IV, T1N3M1). At this time the patient was asymptomatic and refused
chemotherapy; however, radiotherapy was delivered to the supraclavicular
area from 22 April–15 May 2002. As part of the ‘Iressa’ Expanded Access
Programme, treatment with oral gefitinib (‘Iressa’, ZD1839) 250mgday
 1
commenced on 8 July 2002, and a partial response was observed on 26
August 2002 and was confirmed on 4 October 2002. At the last visit (11
April 2003), this response was sustained and there was no recurrence in the
right supraclavicular area. Regression of the bone metastases was also seen,
with a bone scan in January 2003 showing no metastatic lesions in the ribs.
Quality of life improved after 2 months and the treatment was well
tolerated, with mild skin rash (grade 1) and conjunctivitis (grade 1/2),
manageable with routine supportive care. Gefitinib therapy has demon-
strated efficacy in this chemonaive patient, resulting in regression of both
the primary tumour and bone metastases. This patient has now received
gefitinib for 9 months and treatment is ongoing.
Gefitinib (‘Iressa’, ZD1839) as treatment for non-small-
cell lung cancer
E Razis
1, S Papadopoulos
1, D Skarlos
1, M Exarchakos
1,
C Christodoulou
1,MK a r i n a
1, M Xylouri
1 and S Labropoulos
1
1Hygeia Hospital, Athens, Greece
A total of 53 patients with non-small-cell lung cancer (NSCLC) commenced
therapy with gefitinib (‘Iressa’, ZD1839) 250mgday
 1 between March 2001
and November 2002 as part of the ‘Iressa’ Expanded Access Programme.
Three patients received gefitinib as first-line treatment, 16 as second-line,
17 as third-line, 11 as fourth-line and 6 as 4fourth-line. One patient had a
very good partial response to gefitinib, two patients were stable for 13.3 and
2.7þ months and 39 patients progressed during therapy. Nine patients are
still on treatment after o1–5.5 months. The median duration of treatment
for the whole group was 2.85 (range o1–13.3) months. With median
follow-up 8.8 months, 29 patients have died from disease progression and 1
from acute respiratory distress syndrome and disseminated intravascular
coagulation. Time to disease progression was 3.5 months for patients being
treated with first- or second-line gefitinib, 2.4 months for those receiving
third-line gefitinib and 2.9 months for those receiving Xfourth-line
therapy. Median survival after initiation of gefitinib was 4.6 months. Six
patients reported grade 3 toxicities (rash, four patients; diarrhoea, one
patient; congestive heart failure, one patient), and one patient experienced
grade 4 diarrhoea. All toxicities resolved after discontinuing gefitinib.
Tumour epidermal growth factor receptor expression determined by
immunohistochemistry in 24 patients (11 positive, 13 negative) did not
correlate statistically with time to progression or survival, although the
numbers are too small to make definite conclusions. However, some
patients with advanced NSCLC benefit from gefitinib, as demonstrated by a
longer time to progression compared with historical data.
Gefitinib (‘Iressa’, ZD1839) in relapsed non-small-cell
lung cancer
M Reck
1 and U Gatzemeier
1
1Krankenhaus Grohansdorf, Grohansdorf, Germany
A total of 40 patients (12 female and 28 male) with relapsed non-small-cell
lung cancer, received gefitinib (‘Iressa’, ZD1839) between March 2002 and
April 2003. The median age was 58 (range 40–80) years. Four patients
showed evidence of activity with gefitinib. Patient A, a female with
metastatic adenocarcinoma (T2N2M1), had previously received radio-
therapy and six cycles of paclitaxel/gemcitabine. Gefitinib treatment
duration was 6 months. She demonstrated a minor tumour response and
the worst toxicity was grade 1 pruritus. Patient B, a male with
bronchioloalveolar carcinoma (M1), had previously undergone resection
of the left lower lobe and had received two cycles of carboplatin/vinorelbine
and four cycles of gemcitabine. Gefitinib treatment was maintained for 9
months with a best response of stable disease. The patient reported grade 1
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(T3N3M0), had previously received three cycles of carboplatin/paclitaxel
and radiotherapy. Duration of gefitinib treatment was 6.5 months with a
best response of stable disease. The worst toxicity was grade 2 exanthema.
Patient D, a female patient with adenocarcinoma (T4N3M0), had previously
received six cycles of carboplatin/paclitaxel plus N-acetyldinaline (CI-994)/
placebo, two cycles of Bay 38–3441 (an angiogenesis inhibitor) and two
cycles of gemcitabine. Gefitinib treatment resulted in stable disease with no
toxicity and was continued for 7 months. Despite heavy pretreatment with
chemotherapy and radiation therapy gefitinib produced tumour control
over a remarkable period in four out of 40 patients, which was combined
with symptom relief. Treatment with gefitinib was straightforward, feasible
in an outpatient setting and was well tolerated.
Good response in primary tumour, brain, cerebellar and
liver metastases after 2 months’ gefitinib (‘Iressa’,
ZD1839) treatment
ER Roggero
1, G Busi
1 and A Pedrazzini
1
1Humaine Clinica, Locarno, Switzerland
A female patient aged 79 years was first diagnosed in January 2001 with
non-small-cell lung cancer, with metastases in the liver and contralateral
lung. The patient was highly symptomatic (persistent cough, asthenia and
dyspnoea at rest) and received two different chemotherapy regimens, each
for 1 month (vinorelbine/cyclophosphamide then irinotecan/gemcitabine).
However, her general condition deteriorated and she complained of
headaches. Tumour progression was confirmed in the lung and the liver.
The patient then started oral gefitinib (‘Iressa’, ZD1839) 250mgday
 1 in
April 2002, as part of the ‘Iressa’ Expanded Access Programme. At this
time, multiple lesions were documented in the lung, liver, peritoneum,
mediastinum and bones. In addition, a CT scan showed multiple diffuse
brain and cerebellar metastases. At this time, the patient had a performance
status (WHO) of 2. After 2 months’ gefitinib treatment, significant
reductions in the primary tumour and brain metastases were documented
on chest X-ray and CT scan. The patient’s symptoms of fatigue, cough and
pain had improved, and she had a good performance status lasting for
approximately 7 weeks. Although the patient developed herpes zoster
during gefitinib therapy, this responded well to a 10-day course of acyclovir
and a 6-day interruption of gefitinib. Gefitinib treatment continued for 6
months until the patient’s death in September 2002 due to rapid
progression of liver metastases.
Activity of the epidermal growth factor receptor
inhibitor gefitinib (‘Iressa’, ZD1839) in refractory
non-small-cell lung cancer
H Soto Parra
1, R Cavina
1, P Zucali
1, E Campagnoli
1,
F Latteri
1, G Biancofiore
1, G Abbadessa
1, E Morenghi
1
and A Santoro
1 [a]
1Istituto Clinico Humanitas, Rozzano, Italy
The antitumour activity and tolerability of oral gefitinib (‘Iressa’, ZD1839)
250mgday
 1 were assessed in a series of patients with previously treated,
advanced non-small-cell lung cancer (NSCLC), as part of the ‘Iressa’
Expanded Access Programme. To be eligible, patients were required to have
histologically or cytologically proven advanced or metastatic NSCLC, prior
chemotherapy with at least one cisplatin-containing chemotherapy regimen
or contraindication to cytotoxic drugs, Eastern Cooperative Oncology
Group performance status p2, and adequate haematological, renal and
hepatic parameters. Although gefitinib was supplied on a named-patient
basis, all patients provided signed, informed consent. Patient re-evaluation
was performed every 4–6 weeks. A total of 73 consecutive patients were
enrolled, having been diagnosed with NSCLC from February 2001 to April
2003. Nonhaematological toxicity was generally mild: there was grade 3 skin
rash and grade 3 diarrhoea in 5 and 1% of cases, respectively. Response rate,
including complete and partial response, was 10%; an additional 44% of
patients achieved stable disease for an overall disease control of 54%.
Median survival for all patients was 4 months, reaching 6 months for
patients with disease control. Gefitinib has promising activity with a good
toxicity profile in patients with progressive NSCLC who have received one
or two prior chemotherapy regimens. Currently, the development of
epidermal growth factor receptor tyrosine kinase inhibitors represents the
most appealing biological approach for NSCLC. More studies are needed.
Gefitinib (‘Iressa’, ZD1839) in elderly patients with
progressive pretreated non-small-cell lung cancer:
results from the Istituto Clinico Humanitas
H Soto Parra
1, R Cavina
1, P Zucali
1, E Campagnoli
1,F
Latteri
1, G Biancofiore
1, G Abbadessa
1, E Morenghi
1 and A
Santoro
1 [b]
1Istituto Clinico Humanitas, Rozzano, Italy
The antitumour activity and tolerability of gefitinib (‘Iressa’, ZD1839) were
evaluated in a series of elderly patients (aged X70 years) with advanced
non-small-cell lung cancer (NSCLC), as part of the ‘Iressa’ Expanded
Access Programme. From February 2001 to the present, 140 patients with
advanced/metastatic NSCLC, who had received prior chemotherapy or had
a contraindication to cytotoxic drugs, and had an Eastern Cooperative
Oncology Group performance status (PS) p2, were treated with oral
gefitinib 250mgday
 1. From this group, 31 elderly patients were evaluated:
male/female 27/4; PS p1, 21; median age 74 (range 70–82) years. A total of
20 patients had received prior chemotherapy (one regimen, 16 patients; two
regimens, four patients), including 15 who had received platinum-based
chemotherapy. In all, 11 patients had received no previous treatment due to
medical contraindications. No objective response was observed. In total, 18
patients had disease stabilisation (58%) for a median duration of 5.5 (range
1–14) months. Gefitinib was well tolerated; the most frequent toxicities
were grade 1/2 and 3 skin rash in 42 and 10% of cases, respectively, and
grade 1/2 and 3 diarrhoea in 29 and 3%, respectively. Median survival for
all elderly patients and those with stable disease was 3 and 5 months,
respectively, and 1-year survival was 22 and 28%, respectively. This series
shows that gefitinib may achieve disease control in 450% of elderly
patients with progressive NSCLC after one or two chemotherapy regimens,
with an excellent toxicity profile. Gefitinib could be a new therapeutic
option for elderly patients with medical contraindications to standard
chemotherapy.
Analysis of responses to gefitinib (‘Iressa’, ZD1839)
according to epidermal growth factor receptor
expressed as staining intensity or percentage
of immunoreactive cells
H Soto Parra
1, A Santoro
1, R Cavina
1, F Latteri
1, P Zucali
1,
E Campagnoli
1 and M Roncalli
1 [c]
1Istituto Clinico Humanitas, Rozzano, Italy
Of 140 patients with advanced non-small-cell lung cancer treated with oral
gefitinib (‘Iressa’, ZD1839) 250mgday
 1 as part of the ‘Iressa’ Expanded
Access Programme, 36 patients (aged 37–60 years; male:female, 28:8;
performance status p1 in 28 patients; 31 patients previously treated) had
paraffin-embedded tissue available. One patient experienced complete
remission, three had partial remission, 16 had stable disease and 16
progressed (disease control rate 55.6%). The median survival was 4 months
and 1-year survival was 12.3%. Epidermal growth factor receptor (EGFR)
was evaluated by immunohistochemistry using the monoclonal antibody
EGFRAb-10 (clone 111.6, Neomarkers) diluted 1:100 and the En Vision
detection system (Dako). The percentage of neoplastic cells showing
membrane immunoreactivity (IR) was semiquantitatively evaluated (range
0–100%). Response to gefitinib according to EGFR expressed as staining
intensity or percentage of IR cells was (Table 1).
Table 1
Patients,
n
Responses,
n (%)
Disease
control, n (%)
Progression,
n (%)
Staining intensity
2+/3+ 16 4 (25) 8 (50) 8 (50)
0/1+ 20 — 12 (60) 8 (40)
IR cells
HE 15 3 (20) 7 (47) 8 (53)
NLE 21 1 (5) 13 (62) 8 (38)
2+/3+¼medium/strong; 0/1+¼negative/faint staining intensity; HE¼high expres-
sors (X20% IR cells); NLE¼negative/low expressors (0–19% IR cells).
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HE, respectively. According to these results no relationship has been
documented between EGFR expression and disease control. However,
almost all responses were observed in HE patients or those with medium/
strong immunoreactivity. These issues deserve further clinical and
biological evaluation.
Long-term responders to gefitinib (‘Iressa’, ZD1839):
maintenance of tolerability, and propensity for central
nervous system failure
BN Stein
1, D Kotasek
1, FX Parnis
1 and C Bampton
1
1Ashford Cancer Centre, Ashford, Australia
Four patients with metastatic non-small-cell lung cancer were evaluated as
a case series. Characteristics of the patients included: male:female, 3:1; age
range, 46–76 years; performance status (PS), 1; metastases to lung or bone;
and exsmokers, 2. All four patients had previously been treated with
carboplatin/gemcitabine and two had also received weekly docetaxel. One
patient had received palliative radiation to the bone. One patient had a
partial response and three patients had stable disease with previous
therapy. Following treatment with oral gefitinib (‘Iressa’, ZD1839)
250mgday
 1, all patients had a partial response and treatment was
continued for 6–9 months. The responses were clinically meaningful,
which was demonstrated in one patient by an improvement in PS from 2
(dependent on oxygen) to 0 (no longer dependent on oxygen). Two patients
discontinued concomitant opiate therapy. In addition to effects on quality
of life and lifestyle, improvement in pain was experienced within days and
improvement in dyspnoea within weeks. Toxicity was manageable: all four
patients had grade 1 skin rash and two patients had grade 1 diarrhoea, and
there was no evidence of cumulative toxicity during the period of
treatment. Two patients progressed, both in the meninges (one also with
small volume multifocal central nervous system disease); however, the
primary disease remained controlled.
Long-term disease stabilisation with gefitinib (‘Iressa’,
ZD1839) treatment in a patient with advanced non-
small-cell lung cancer and multiple metastatic sites
R van der Kamp
1, MGJ Koolen
1 and HM Jansen
1
1Amsterdam, The Netherlands
In July 2002, a 56-year-old female ex-smoker presented with symptoms of
dysarthria, paraesthesia, decreased right-leg strength, pain in the right side
of the thorax, dyspnoea and a dry cough, which had all appeared 2 months
previously. A CT scan revealed a tumour that had invaded the
mediastinum, with multiple pathological lymph nodes and multiple
metastases in the lung. Multiple brain metastases were also observed by
MRI scan. The disease was histologically confirmed as stage IV non-small-
cell lung cancer (NSCLC). Owing to the relatively good physical condition
of the patient (Eastern Cooperative Oncology Group performance status 1)
and the low chance of success of chemotherapy due to the brain metastases,
initial treatment consisted of radiotherapy of the brain (5 4Gy) in July
2002. Treatment with oral gefitinib (‘Iressa’, ZD1839) 250mgday
 1 was
initiated in August 2002. In September 2002 the patient had a mild skin
rash and nausea. Celecoxib had also been used for some weeks and, once
the dose of this comedication was decreased, the skin rash disappeared. In
September and October 2002, the patient’s walking ability seemed to be
becoming progressively impaired; however, the deterioration was mild and
the condition has since stabilised. At her most recent visit, in March 2003,
the patient’s overall condition was stable and gefitinib treatment is
ongoing. This patient with advanced NSCLC, including multiple brain
metastases, has experienced disease stabilisation for more than 9 months
while on gefitinib treatment. This is an unexpectedly long period of stable
disease, to which gefitinib may have contributed.
Long-term response induced by gefitinib (‘Iressa’,
ZD1839) in a patient with bronchioalveolar cell
carcinoma
N van Zandwijk
1 [a]
1The Netherlands Cancer Institute, Amsterdam, The Netherlands
A 65-year-old female nonsmoker was diagnosed with bronchioalveolar
carcinoma (BAC) in 1997 and underwent left-lung pneumectomy. In March
1999, disease recurrence (stage IV) was identified with a slowly progressing
invasion in the other lung. The patient was treated with 1 dose of cisplatin/
gemcitabine followed by gemcitabine alone from February to October 2000,
which resulted in stable disease. However, in October the patient’s
condition deteriorated, with a considerable decline in lung function,
reducing her performance status (PS) (WHO) to 2–3, and so prednisone
therapy was initiated. Treatment with oral gefitinib (‘Iressa’, ZD1839)
began in July 2001, leading to a gradual improvement of pulmonary
symptoms over 3 months, with prednisone reduced and finally discon-
tinued in June 2002. An X-ray revealed a gradual clearing of the right lung
in January 2002, meeting the criteria for a partial response, and the
patient’s PS had improved to 1. The patient initially experienced mild
diarrhoea, and also reported intermittent skin rashes. Gefitinib has
provided a long-term response for this patient with stage IV non-small-
cell lung cancer. Treatment is ongoing after more than 9 months and the
partial response has been sustained. Significant quality-of-life improve-
ments have been observed, and the patient’s PS is minimally impaired
despite pulmonary infections. This case report demonstrates that a
relatively slow onset of response to therapy may be seen with BAC
patients. In addition, patients with severely impaired pulmonary function
may show a favourable response to epidermal growth factor receptor
inhibitors, such as gefitinib.
Quality-of-life benefits for a patient with non-small-cell
lung cancer and brain metastases taking gefitinib
(‘Iressa’, ZD1839)
N van Zandwijk
1 [b]
1The Netherlands Cancer Institute, Amsterdam, The Netherlands
Stage IV non-small-cell lung cancer with lymphangitic spread was
diagnosed in a 55-year-old male ex-smoker with no significant medical
history in October 1999. He was treated with cisplatin and gemcitabine for
3 months followed by gemcitabine alone for 4 months, and a partial
response was achieved. However, the disease recurred in September 2000
and oral paclitaxel was given until disease progression in June 2001.
Treatment with gefitinib (‘Iressa’, ZD1839) began in July 2001. After an
initial improvement, pleural fluid increased and evacuation and subsequent
pleurodesis were performed. Thereafter, a gradual symptomatic improve-
ment was observed and the patient resumed work in January 2002. His
performance status (WHO) was 0–1. In September 2002, impaired
coordination indicated the development of brain metastases, with
examination revealing approximately 20 small lesions. A chest X-ray
showed stable disease. Radiotherapy to the brain (10 3Gy) was
administered in October 2002 and gefitinib treatment continued. Symptom
improvement occurred gradually and the disease stabilised. The patient
resumed work (60%) again in May 2003, with a good general condition
and WHO performance status 1–2. In this case, gefitinib produced disease
stabilisation and excellent quality-of-life benefits, with the patient
able to return to work despite advanced metastatic disease. Combined
radiotherapy and gefitinib treatment were well tolerated and resulted
in a durable clinical response, which has currently lasted for more
than 6 months. Gefitinib did not protect against brain metastases; however,
the treatment of brain metastases during gefitinib therapy may be
worthwhile.
Disease stabilisation following gefitinib (‘Iressa’,
ZD1839) therapy in a patient with metastatic non-
small-cell lung cancer and very poor performance status
MD Vincent
1
1London Regional Cancer Centre, London, Canada
In January 2002, a 56-year-old male smoker presented with non-small-cell
lung cancer metastases to the ipsilateral lung and pleura, and an Eastern
Cooperative Oncology Group performance status (PS) of 1. The patient had
been exposed to asbestos in 1974 although no related lung complications
were present. Four cycles of carboplatin plus paclitaxel were administered.
The patient experienced a partial response to this treatment regimen but
had a bad allergic reaction to paclitaxel that required in-patient
administration. He had also become very emaciated and hypercalcaemic,
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oxygen. Following initiation of gefitinib the patient experienced a 2-month
period of disease stabilisation and symptom control, for which he was
grateful. Minor improvements in pain, dyspnoea and quality of life were
evident within 1 month of starting gefitinib, and the patient’s serum
alkaline phosphatase declined from 201 to 140IUL
 1 during this time.
Gefitinib was well tolerated with no side effects. Although the patient died
after 3 months of treatment, it is probable that gefitinib therapy held his
disease in check for 2 months, when he would otherwise have continued to
decline rapidly. Moreover, it is speculated that earlier initiation of gefitinib
may have stabilised the patient’s disease when his PS had been better.
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